Feb 08, 2021 7:30am EST Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Jan 27, 2021 8:30am EST Veru to Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call on February 10th
Jan 19, 2021 8:30am EST Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
Jan 04, 2021 8:30am EST Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021
Dec 14, 2020 7:30am EST Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targeting Agent, for Endocrine Resistant Metastatic Breast Cancer
Dec 14, 2020 7:00am EST VERU-111, Cytoskeleton Disruptor, Demonstrates Efficacy in Preclinical Models of Human Triple Negative Breast Cancer
Dec 09, 2020 6:55am EST Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast Cancer
Dec 09, 2020 6:30am EST Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results
Nov 23, 2020 8:30am EST Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th
Sep 29, 2020 8:30am EDT Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer
